Repeat revascularization is a faulty end point for clinical trials.

Kazi, Dhruv S, and Mark A Hlatky. 2012. “Repeat Revascularization Is a Faulty End Point for Clinical Trials.”. Circulation. Cardiovascular Quality and Outcomes 5 (3): 249-50.